TG Therapeutics(US:TGTX) Benzinga·2026-01-13 22:05Core Viewpoint - TG Therapeutics, Inc. has released optimistic preliminary revenue estimates for Q4 2025 and a positive outlook for 2026, leading to a rise in stock price [1][3]. Revenue Estimates - The company expects Briumvi U.S. net product revenue to be approximately $182 million for Q4 2025 and $594 million for the full year of 2025, with total global revenue for 2025 estimated at around $616 million [2]. - For 2026, TG Therapeutics is targeting total global revenue of approximately $875 to 900 million, including Briumvi U.S. net product revenue of about $825 to 850 million [2]. Market Performance - Briumvi has shown strong commercial performance in 2025, indicating a significant market share capture since its launch, which positions TG Therapeutics for long-term revenue growth and cash flow [3]. - Following the announcement, TG Therapeutics shares increased by 6.60%, reaching a price of $29.71 in extended trading [3].